High-throughput screening identifies the activity of histone deacetylase inhibitors in patient-derived models of soft tissue sarcoma
Quisinostat demonstrated strong preclinical activity and synergy with standard-of-care doxorubicin in models of UPS and LMS.
Authors
- Ailsa J. Oswald (ORCID: https://orcid.org/0000-0002-0702-3892)
- William Kerrison (ORCID: https://orcid.org/0000-0002-3341-2103)
- Valerie G. Brunton (ORCID: https://orcid.org/0000-0002-7778-8794)
- Ailith Ewing (ORCID: https://orcid.org/0000-0002-2272-1277)
- Morwenna Muir (ORCID: https://orcid.org/0000-0001-5835-3886)
- Ioanna Nixon (ORCID: https://orcid.org/0000-0003-3223-0700)
- Mary K. Danks
- Paul H. Huang (ORCID: https://orcid.org/0000-0003-3972-5087)
- Jayne Culley (ORCID: https://orcid.org/0009-0002-5024-4460)
- John C. Dawson (ORCID: https://orcid.org/0000-0001-5713-1026)
- John P. Thomson (ORCID: https://orcid.org/0000-0002-1630-3159)
- Henry Beetham (ORCID: https://orcid.org/0000-0002-8446-2485)
- Neil O. Carragher (ORCID: https://orcid.org/0000-0001-5541-9747)
- Piotr Manasterski (ORCID: https://orcid.org/0000-0002-8700-5458)
- Richard Elliott (ORCID: https://orcid.org/0009-0002-0174-5488)
- Rashi Krishna
Institutions
- Institute of Cancer Research (GB)
- University of Strathclyde (GB)
- Beatson West of Scotland Cancer Centre (GB)
- Edinburgh Cancer Research (GB)
- Institute of Cancer Research (CA)
- Institute of Genetics and Cancer (GB)
- University of Edinburgh (GB)
Publication Details
- Journal
- Cancer Biology & Therapy
- Published
- 2025-11-30
- DOI
- https://doi.org/10.1080/15384047.2025.2589666
- Primary Topic
- Histone Deacetylase Inhibitors Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00